Switching from Mounjaro to Wegovy: What You Need to Know

Both Mounjaro and Wegovy belong to a class of medicines called GLP-1 receptor agonists, which have revolutionised the treatment of obesity and weight management. However, the medicines have several important clinical differences. Our detailed Mounjaro vs Wegovy comparison guide explains the differences in mechanism, expected weight loss, dosing schedules and suitability for different patients.

Mounjaro (tirzepatide) is a dual-action medicine that targets both GLP-1 and GIP receptors, potentially offering enhanced weight loss effects. Clinical studies have shown average weight loss of up to 20% of body weight at higher doses.

Wegovy (semaglutide) is a selective GLP-1 receptor agonist that has demonstrated significant weight loss results, with patients typically losing around 15% of their body weight. Notably, Wegovy is the only GLP-1 medicine currently licensed in the UK to reduce the risk of major cardiovascular events such as heart attacks and strokes in people with obesity and established heart disease.

There are several legitimate reasons why patients and GPs may consider transitioning from Mounjaro to Wegovy:

Side Effect Management
While both medicines share similar side effect profiles, individual responses can vary significantly. Some patients find Wegovy more tolerable, experiencing fewer gastrointestinal symptoms such as nausea, vomiting, or abdominal discomfort. If you want a detailed breakdown of symptoms and management strategies, see our Mounjaro side effects and how to treat them guide.

Cardiovascular Benefits
For patients with existing cardiovascular risk factors or established heart disease, Wegovy's proven cardiovascular benefits may make it the preferred choice. This additional protective effect extends beyond weight loss to encompass broader health outcomes.

Economic Considerations
Cost differences between medicines can influence treatment decisions. Recent price adjustments may make Wegovy a more economically viable option for some patients, ensuring continued access to effective weight management therapy.

Treatment Optimisation
If weight loss progress has plateaued or side effects are limiting adherence to your current regimen, switching medicines may help reinvigorate your weight management journey.

The transition from Mounjaro to Wegovy should always be conducted under professional medical supervision.

Happy Pharmacy's Recommended Approach
Your prescriber may recommend a seven-day interval between stopping Mounjaro and starting Wegovy. Tirzepatide is not fully cleared after seven days. Your prescriber may recommend a longer interval, especially if side effects persist. Do not take both medicines together.

What to expect during the switch:

1. 7-day gap: If prescribed, count seven days from your final Mounjaro injection before starting Wegovy
2. Starting fresh: Begin with the lowest Wegovy dose (0.25mg) regardless of your previous Mounjaro dose
3. Gradual increase: Your prescriber reviews increases after four weeks at each step; increases may be delayed if needed
4. ⚠️ Side effects may return: Mild nausea, stomach upset, or changes in appetite are normal initially

Timeline:

• Day 0: Final Mounjaro dose
• Days 1–6: No further Mounjaro or Wegovy injections
• Day 7: Start Wegovy 0.25 mg only if prescribed
• Wegovy weeks 1–4: Continue 0.25 mg weekly
• Wegovy weeks 5–8: Increase to 0.5 mg only if prescribed
• Continue: Following the standard Wegovy dose schedule

After the interval agreed with your prescriber, Wegovy starts at 0.25 mg weekly. The usual dose schedule is below; your prescriber may delay increases if needed:

• Weeks 1-4 (of Wegovy treatment): 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17 onwards: 2.4 mg weekly (maintenance dose)

This methodical approach allows your body to adapt progressively, minimising potential side effects and maximising treatment tolerability.

What to Expect
During the initial weeks of switching, you may experience:

• Temporary return of mild side effects such as nausea, constipation, or changes in appetite as your body adjusts to the new medicine
• Appetite fluctuations during the first few weeks of treatment
• Variable weight loss patterns as your body responds to the different mechanism of action

Maintaining Lifestyle Modifications
The success of any weight management medication depends significantly on maintaining healthy lifestyle behaviours. Continue to focus on:

• Balanced nutrition with emphasis on whole foods and appropriate portion sizes
• Regular physical activity appropriate to your fitness level and medical clearance
• Adequate hydration to support overall health and potentially reduce side effects
• Sleep hygiene as quality rest supports metabolic health and weight management

Regular follow-up with your GP or prescribing clinician is essential during the transition period. This monitoring allows for:

• Assessment of treatment tolerance and effectiveness
• Dose adjustments if needed
• Management of any emerging side effects
• Ongoing support and encouragement

Research in the field of incretin mimetic interchange has provided valuable insights into the safety and efficacy of switching between these medicines. Studies have demonstrated that transitioning between GLP-1 receptor agonists is generally well-tolerated when conducted appropriately, with patients able to maintain therapeutic benefits throughout the transition process.

The growing body of evidence supports the concept that individualised treatment approaches, including medicine switching when clinically indicated, can optimise patient outcomes in weight management therapy.

While switching between these medicines is generally safe, certain considerations are important:

• Never adjust doses independently – always follow your GP's or prescribing clinician's specific instructions
• Report any concerning symptoms promptly to your medical team
• Maintain consistent injection technique and site rotation to prevent complications
• Be aware of drug interactions and inform all healthcare providers about your current medicines

The decision to switch from Mounjaro to Wegovy should be made collaboratively with your GP or prescribing clinician, considering:

• Your individual response to current treatment
• Side effect profile and tolerability
• Cardiovascular risk factors
• Personal preferences and lifestyle factors
• Economic considerations
• Long-term health goals

Switching weight management medicines is a common part of optimising your treatment plan. With appropriate medical supervision and realistic expectations, most patients successfully transition between these medicines while maintaining their weight management progress.

Remember that both Mounjaro and Wegovy are tools to support your broader lifestyle changes – they work most effectively when combined with sustainable dietary modifications and regular physical activity. The goal is not just weight loss, but the development of lasting healthy habits that will support your long-term wellbeing.